CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125

POLICY TYPE          Parliamentary submission
DATE                2014-03-26
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE  Parliamentary submission
DATE  2017-04-06
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE  Response to consultation
DATE  2016-03-19
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Response:
Consultation on the Prescription Drug List: Naloxone

Health Canada - Prescription Drug Stewardship Committee

March 19, 2016
Harms associated with opioids and other psychoactive prescription drugs
https://policybase.cma.ca/link/policy11535

POLICY TYPE
Policy document

DATE
2015-05-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE          Response to consultation
DATE                2018-12-04
TOPICS              Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on regulatory amendments regarding tramadol
https://policybase.cma.ca/link/policy13927

POLICY TYPE  Response to consultation
DATE       2018-08-14
TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE  Response to consultation
DATE  2018-07-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035

POLICY TYPE
Parliamentary submission

DATE
2013-11-27

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Non-prescription availability of low-dose codeine products
https://policybase.cma.ca/link/policy13734

POLICY TYPE  Response to consultation
DATE  2017-11-7
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model
https://policybase.cma.ca/link/policy13932

POLICY TYPE
Policy endorsement

DATE
2018-10-31

TOPICS
Population health, health equity, public health

Documents

October 13, 2018
Res. Human Officer

We note with interest the decision to expand the "Consumption and Treatment Services" model in Ontario in response to the Public Health Act. We are concerned about the potential impact of this model on the health and well-being of Canadians, particularly vulnerable populations.

While we commend the government’s efforts to expand support services for people living with addictions, we are concerned about the potential impact of this model on the health and well-being of Canadians, particularly vulnerable populations. The current model, which focuses on consuming cannabis in designated areas, may not be the most effective approach to addressing the needs of these populations.

As a general principle, we believe that individual choice should be respected, provided it does not negatively impact others. However, in the case of cannabis consumption, it is important to consider the potential negative impacts on public health and safety.

We recommend that the government consider alternative models that prioritize health and well-being, such as expanded access to addiction treatment services and harm reduction programs. These models would be more effective in addressing the needs of Canadians living with addictions.

We encourage the government to engage with stakeholders, including healthcare providers, community organizations, and individuals living with addictions, to ensure that any new policies and programs are evidence-based and inclusive.

We look forward to ongoing discussions to ensure that the health and well-being of Canadians are protected and supported.

Sincerely,

Canadian Medical Association
 Proposed amendments to the marihuana for medical purposes regulations

https://policybase.cma.ca/link/policy11293

POLICY TYPE
Response to consultation

DATE
2014-07-11

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/link/policy11114

POLICY TYPE Response to consultation

DATE 2014-03-17

TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

Policy Type: Parliamentary submission
Date: 2016-10-18
Topics: Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents

Opening Statement

House of Commons
Standing Committee on Health

Dr. Jeff Blackmer
Vice-President, Medical Professionals
Canadian Medical Association
Ottawa
October 18, 2016

Check against delivery
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE  
Policy endorsement

DATE  
2018-08-30

TOPICS  
Pharmaceuticals, prescribing, cannabis, drugs

Documents

Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott

August 9, 2018

The Ontario Health Coalition

Premier Doug Ford
245 collage St
Toronto, ON M5T 1C3

Honourable Christine Elliott
Minister of Health and Long-Term Care
41 Albert St, 5th Fl
Toronto, ON M5H 3C1

We are a group of organizations that represent hundreds of thousands of residents of Ontario. We are writing to you in the wake of the ongoing overdose crisis in Ontario to urge the government to take immediate action to ensure that life-saving supervised consumption and overdose prevention sites (SCOPS) are opened in the province. SCOPS provide a safe and regulated environment for individuals to use drugs under the supervision of trained professionals, while at the same time offering support and treatment options to those in need.

We understand that the current legal framework makes it difficult to establish SCOPS in Ontario. However, we believe that the health and safety of our communities are at stake, and the time for action is now. SCOPS have been shown to reduce drug-related deaths, emergency department visits, and overall drug use in other jurisdictions. They also provide a gateway to treatment and harm reduction services, which are desperately needed in Ontario.

We urge the government to take urgent steps to establish SCOPS in Ontario. This is not only a humane and necessary response to the overdose crisis, but it is also a critical step towards addressing the root causes of addiction and improving the health outcomes of those affected by drug use.

Sincerely,
The Ontario Health Coalition
Tamper Resistance under the Controlled Drugs and Substances Act

https://policybase.cma.ca/link/policy11295

POLICY TYPE
Response to consultation

DATE
2014-08-26

TOPICS
Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents